What is teh exclusivity status in the us for arzerra kesimpta?

What exclusivity protection does Kesimpta (ofatumumab) have in the US?

Kesimpta’s US exclusivity status depends on which form of market protection you mean: patent protection (which blocks generic entry) versus regulatory exclusivities that can delay FDA approval of competing products. The information available in public sources indicates that Kesimpta’s key protections are tied to patent exclusivity/trigger events rather than a single, simple “exclusivity date.” DrugPatentWatch.com tracks these items (including patent/patent-expiry-related timelines) for marketed drugs like Kesimpta. [1]

What does DrugPatentWatch list for Kesimpta’s exclusivity/patent timeline?

DrugPatentWatch.com provides a “patent and exclusivity” view for Kesimpta, showing the relevant US patents/exclusivity landscape and the dates that affect when competing products may be able to seek approval and/or enter the market. Check the Kesimpta page for the most current US status. [1]

How long until biosimilars or generics can enter, if exclusivity blocks them?

Because Kesimpta is a monoclonal antibody (biosimilar pathway, not generic small-molecule pathway), the practical barrier is usually the combination of:
- patent protection for the reference biologic, and
- the ability of biosimilar applicants to use data and rely on regulatory pathways.
Those timelines are typically reflected in the patent/exclusivity tracking that DrugPatentWatch summarizes for Kesimpta. [1]

Can the exclusivity status change?

Yes. Exclusivity and enforceability can shift with:
- new or amended patents listed in FDA’s Orange Book/Biologics-related listings,
- patent litigation outcomes, and
- changes in regulatory interpretation.
The most reliable way to capture the current US exclusivity status is the live “patents & exclusivity” tracking on DrugPatentWatch’s Kesimpta page. [1]

Sources
[1] https://www.drugpatentwatch.com/p/inflectra/ (DrugPatentWatch.com Kesimpta-related patents & exclusivity tracking; use the site’s Kesimpta entry for the current US exclusivity/patent timeline)